Literature DB >> 26380007

Efficacy of high-intensity focused ultrasound ablation for adenomyosis therapy and sexual life quality.

Ling Long1, Jinyun Chen2, Yu Xiong3, Min Zou3, Yongbin Deng3, Li Chen3, Zhibiao Wang1.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the efficacy, safety and sexual life quality outcomes of ultrasound-guided high-intensity focused ultrasound (HIFU) ablations for the treatment of patients with symptomatic adenomyosis and uterine volumes >200 cm(3).
METHODS: In our prospective clinical trial 47 patients with uterine volumes >200 cm(3) and symptomatic adenomyosis were treated with single treatment sessions of ultrasound-guided HIFU ablations. Beside uterus and adenomyosis lesion size reductions, outcome measures were symptom severity score (SSS), visual analogue scale (VAS) of dysmenorrhea, female sexual function index (FSFI) scores and the incidence of complications.
RESULTS: In all 47 patients, the adenomyosis lesions sizes were significantly reduced 12 months after the interventions (P<0.01). The SSS and dysmenorrhea VAS scores were significantly reduced 12 months after the interventions (P<0.01) and the FSFI scores gradually improved during 12 months after the HIFU ablations (P<0.001). No serious complication occurred.
CONCLUSION: Ultrasound-guided HIFU ablation is a safe and effective noninvasive alternative for the treatment of uterine volumes >200 cm(3) with symptomatic adenomyosis. Particularly maintaining the integrity of patients' uteri leads to significant FSFI score improvements, which were essentially reduced before the HIFU treatments.

Entities:  

Keywords:  High-intensity focused ultrasound; adenomyosis; and dysmenorrhea; female sexual function index; symptom severity score

Year:  2015        PMID: 26380007      PMCID: PMC4565390     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  19 in total

1.  Society of Interventional Radiology clinical practice guidelines.

Authors:  David Sacks; Tricia E McClenny; John F Cardella; Curtis A Lewis
Journal:  J Vasc Interv Radiol       Date:  2003-09       Impact factor: 3.464

Review 2.  Pathology and physiopathology of adenomyosis.

Authors:  Christine Bergeron; Frederic Amant; Alex Ferenczy
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2006-03-24       Impact factor: 5.237

3.  Feasibility of MRI-guided high intensity focused ultrasound treatment for adenomyosis.

Authors:  Tien-Ying Fan; Lian Zhang; Wenzhi Chen; Yinjiang Liu; Min He; Xiu Huang; Franco Orsi; Zhibiao Wang
Journal:  Eur J Radiol       Date:  2011-06-29       Impact factor: 3.528

4.  The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata.

Authors:  James B Spies; Karin Coyne; Noureddine Guaou Guaou; Deneane Boyle; Kerry Skyrnarz-Murphy; Sheila M Gonzalves
Journal:  Obstet Gynecol       Date:  2002-02       Impact factor: 7.661

5.  Ultrasound-guided high-intensity focused ultrasound ablation for adenomyosis: the clinical experience of a single center.

Authors:  Min Zhou; Jin-Yun Chen; Liang-Dan Tang; Wen-Zhi Chen; Zhi-Biao Wang
Journal:  Fertil Steril       Date:  2010-11-10       Impact factor: 7.329

6.  MR imaging of diffuse adenomyosis changes after GnRH analog therapy.

Authors:  Izumi Imaoka; Susan M Ascher; Kazuro Sugimura; Kentaro Takahashi; Hong Li; Felicia Cuomo; James Simon; Lori L Arnold
Journal:  J Magn Reson Imaging       Date:  2002-03       Impact factor: 4.813

7.  Feasibility of laparoscopic high-intensity focused ultrasound treatment for patients with uterine localized adenomyosis.

Authors:  Zhu Yang; You-De Cao; Li-Na Hu; Zhi-Biao Wang
Journal:  Fertil Steril       Date:  2008-04-28       Impact factor: 7.329

8.  Changes in female sexual function after pelvic organ prolapse repair: role of hysterectomy.

Authors:  Elisabetta Costantini; Massimo Porena; Massimo Lazzeri; Luigi Mearini; Vittorio Bini; Alessandro Zucchi
Journal:  Int Urogynecol J       Date:  2013-01-30       Impact factor: 2.894

9.  Genitourinary symptoms in patients with adenomyosis.

Authors:  Murat Ekin; Hüseyin Cengiz; Emine Öztürk; Cihan Kaya; Levent Yaşar
Journal:  Int Urogynecol J       Date:  2012-08-02       Impact factor: 2.894

10.  Adenomyosis: prevalence, risk factors, symptoms and clinical findings.

Authors:  O Yeniel; T Cirpan; M Ulukus; A Ozbal; G Gundem; S Ozsener; O Zekioglu; H Yilmaz
Journal:  Clin Exp Obstet Gynecol       Date:  2007       Impact factor: 0.146

View more
  4 in total

1.  Ultrasound-guided transcervical radiofrequency ablation for symptomatic uterine adenomyosis.

Authors:  Ning Hai; Qingxiang Hou; Xiaoping Ding; Xiangping Dong; Meijuan Jin
Journal:  Br J Radiol       Date:  2016-10-28       Impact factor: 3.039

Review 2.  A systematic review of outcome reporting and outcome measures in studies investigating uterine-sparing treatment for adenomyosis.

Authors:  T Tellum; M Omtvedt; J Naftalin; M Hirsch; D Jurkovic
Journal:  Hum Reprod Open       Date:  2021-08-07

3.  Quercetin alleviates generalized hyperalgesia in mice with induced adenomyosis.

Authors:  Jichan Nie; Xishi Liu
Journal:  Mol Med Rep       Date:  2017-08-14       Impact factor: 2.952

Review 4.  Current status of high-intensity focused ultrasound for the management of uterine adenomyosis.

Authors:  Vincent Y T Cheung
Journal:  Ultrasonography       Date:  2017-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.